Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Carrillo Munoz Silvia, RN

Blood (2019) 134 (Supplement_1): 5921.

https://doi.org/10.1182/blood-2019-130873

Published: 2019

Journal Articles

Hyperimmunoglobulin E Syndrome (HIES) Treated with Thalidomide Plus Dexamethasone with Encouraging Results

Rafael Hurtado Monroy, MD, Pamela Denisse Soberanis Pina, MD, Juan Jose Calva Mercado, Jose Pablo Vargas Viveros, Catalina Romo Aguirre

Blood (2017) 130 (Supplement 1): 4822.

https://doi.org/10.1182/blood.V130.Suppl_1.4822.4822

Published: 2017

Journal Articles

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera Ceballos, MD, Judith Cruz Velazquez, Silvia Carrillo Munos, RN

Blood (2013) 122 (21): 5172.

https://doi.org/10.1182/blood.V122.21.5172.5172

Published: 2013

Journal Articles

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Pablo Vargas-Viveros, MD, Rafael Hurtado Monroy, MD, Myrna Candelaria-Hernandez, MD

Blood (2013) 122 (21): 5252.

https://doi.org/10.1182/blood.V122.21.5252.5252

Published: 2013

Journal Articles

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Pablo Vargas, MD, Roberto Ovilla, MD, Martha Alvarado, MD, Manuel Lopez, MD, Rafael Hurtado Monroy, MD., Juan_Carlos Solis, MD, Alejandro Limon, MD, Gladys Agreda, MD, Salvador Silva, MD, Juan Julio Kassack, MD, Saida Zavala, MD, Carlos Aguilar, MD, Enrique Baez, Esperanza Barrera, MD, Antonio Osuna, MD, Javier Morales, MD, Aquileo Herrera, MD

Blood (2012) 120 (21): 5067.

https://doi.org/10.1182/blood.V120.21.5067.5067

Published: 2012

Journal Articles

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

Blood (2011) 118 (21): 3766.

https://doi.org/10.1182/blood.V118.21.3766.3766

Published: 2011

Journal Articles

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Luis Fernando Cortázar-Benítez, Pablo Vargas Viveros, MD, Alfredo Aiza Alvarez, Rafael Hurtado Monroy, MD.

Blood (2011) 118 (21): 5278.

https://doi.org/10.1182/blood.V118.21.5278.5278

Published: 2011

Journal Articles

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

Luis Fernando Cortázar-Benítez, R.M. Rojas Sotelo, Pablo Vargas-Viveros, MD, Rafael Hurtado-Monroy, MD., Catalina Romo Aguirre, MD, Jorge Valenzuela Tamariz, MD, Alejandra Zárate, MD, Sergio Masse, MD

Blood (2011) 118 (21): 4934.

https://doi.org/10.1182/blood.V118.21.4934.4934

Published: 2011

Journal Articles

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

Blood (2009) 114 (22): 2199.

https://doi.org/10.1182/blood.V114.22.2199.2199

Published: 2009

Journal Articles

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Pablo Vargas-Viveros, M.D., Rafael Hurtado Monroy, MD, Eduardo Cervera, MD, Carlos Best, M.D., Alvaro Aguayo, M.D., Myrna Candelaria, MD

Blood (2009) 114 (22): 4291.

https://doi.org/10.1182/blood.V114.22.4291.4291

Published: 2009

Journal Articles

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Blood (2008) 112 (11): 4275.

https://doi.org/10.1182/blood.V112.11.4275.4275

Published: 2008

Journal Articles

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Rafael Hurtado Monroy, MD, Pablo Vargas-Viveros, MD, Eduardo Cervera, MD, Myrna Candelaria, MD, Alvaro Aguayo, MD, Emma Gallardo, MD, Eucario Leon, MD, Juan Labardini, MD, Ricardo Sosa, MD, Rogelio Paredes, MD, Fernando Romero, MD, Oscar Perez, MD, Omar Coronel-Ayala, MD

Blood (2004) 104 (11): 1015.

https://doi.org/10.1182/blood.V104.11.1015.1015

Published: 2004

NARROW

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Hyperimmunoglobulin E Syndrome (HIES) Treated with Thalidomide Plus Dexamethasone with Encouraging Results

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph +) In IM-Resistant Disease. Report Of 14 New Cases From A Single Center In Mexico

Significant Improvement In Quality Of Life (QoL) In Patients With Chronic Myeloproliferative Neoplasms and Myelofibrosis Treated With JAK-1 and JAK-2 Inhibitor Ruxolitinib. A Single Institution Experience In Mexico

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years,

Hemolytic Intravascular Anemia (HIA) Microangiopathic-Like and Deep Venous Thrombosis (DVT) Due to Ozone Exposure: Case Report

Hyper Immunoglobulin E Syndrome (HIES): Report of a New Case Treated with Omalizumab and Dexametasone

Imatinib Long Term Effects (ILTE) Study: An International Study to Evaluate Long-Term Effects in CML Patients.

The Age of Mexican Patients with Chronic Myeloid Leukemia (CML) Ph+ Is Quite Younger Than the Reported in USA and European Series.

Nilotinib (AMN107) Can Induce Complete Cytogenetic Responses (CCyR) and Molecular Responses in Patients (Pts) with Advanced Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib Mesylate (IM). Report of the Compassionate Use Program of Nilotinib in Mexico

Imatinib Alone (IA) Vs. Imatinib + Ara-C (IMAC): A Randomized Phase III Clinical Trial for the Treatment of Early Phase (EP) Chronic Myeloid Leukemia (CML) Ph+. Preliminary Report of Mexican Cooperative Leukemia Group (GRUMELA).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only